← Leaderboards
Kavitha Yaddanapudi
University Of Louisville
$3,421,422
Attributed
$3,819,250
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $992.1K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,819,250 · 8
By mechanism
R21$1,522,976 · 4
P20$1,254,371 · 3
R01$1,041,903 · 1
Top collaborators
- Chi Li3 shared
Most similar at University Of Louisville
Same institution · by research overlap
- Robert A. Mitchell$6,052,736
- Martha E Bickford$21,342,181
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellCellsTumorResistanceTumor ImmunityMalignant Neoplasm Of LungMouse ModelImmuneCancer PatientResponseMolecularMalignant NeoplasmsMediatingIn VivoImmunotherapeutic AgentNon-Small-Cell Lung CarcinomaInsightCd8b1 GeneLung NeoplasmsClinically RelevantEffector T CellCd8-Positive T-LymphocytesCancer CellGenerations
Grant awards (16)
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer$353,044
R01 · FY2025 · CA · contact PI
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer$335,530
R01 · FY2024 · CA · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$217,150
P20 · FY2024 · GM · contact PI
A Stem Cell Based Exosomal Vaccine for the Prevention of Cancer$173,764
R21 · FY2024 · CA · contact PI
A lung cancer vaccine based on exosomes of induced pluripotent stem cells$402,401
R21 · FY2023 · CA
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer$353,329
R01 · FY2023 · CA · contact PI
A Stem Cell Based Exosomal Vaccine for the Prevention of Cancer$219,491
R21 · FY2023 · CA · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$16,892
P20 · FY2023 · GM · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$270,817
P20 · FY2022 · GM · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$271,697
P20 · FY2021 · GM · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$167,475
R21 · FY2021 · CA · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$273,000
P20 · FY2020 · GM · contact PI
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine$200,970
R21 · FY2020 · CA · contact PI
A Novel Vaccination Stratagem for Lung Cancer$163,125
R21 · FY2016 · CA · contact PI
A Novel Vaccination Stratagem for Lung Cancer$195,750
R21 · FY2015 · CA · contact PI
PROJ 12: STEM CELL-BASED VACCINE FOR CANCER PROPHYLAXIS$204,815
P20 · FY2011 · RR · contact PI